Form D · Biotechnology
BALX Holdings, LLC
Boston, MA · CIK 0001668511
Offering snapshot reported Oct 21, 2016 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 11, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 21, 2016 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| May 3, 2016 | Initial | $6,982,012 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-272997
Source: Form D, filed Oct 21, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Belluck | Director |
| Philip Borden | Director |
| Kurt Brykman | Director |
| James A. Datin | Director, Executive |
| Jeremy Goldberg | Director |
| Michael J. Lehmann | Director |
| Todd Lynch | Executive |
| Mike Magliochetti | Director |
| Max Osofsky | Director |
| Caroline Popper | Director |
| Afshin Safavi | Director, Executive |
| Craig Stern | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Riverside Partners, Llc 699 Boylston Street, 14 Th Floor
Boston, MA, 02116
Boston, MA, 02116